Patent application number | Description | Published |
20100322933 | INTRAOPERATIVE TRIFUNCTIONAL ANTIBODY APPLICATION FOR PROPHYLAXIS OF INTRAPERITONEAL TUMOR CELL DISSEMINATION - The invention describes the use of trifunctional bispecific and trispecific antibodies for destroying tumor cells which e.g. are disseminated intraperitoneally due to a surgical intervention, wherein the antibody is administered intraoperatively, preferably directly locally into the abdominal cavity. | 12-23-2010 |
20120095192 | USE OF TRIFUNCTIONAL BISPECIFIC ANTIBODIES FOR THE TREATMENT OF TUMORS ASSOCIATED WITH THE CD133+/EPCAM+ CANCER STEM CELLS - Use of a trifunctional bispecific antibody having the following properties of a) binding to a T cell; b) binding to EpCAM as tumor-associated antigen on a tumor cell wherein the tumor cell additionally carries the membrane bound glycoprotein CD 133; c) binding by its Fc portion to Fc receptor-positive cells for the preparation of a pharmaceutical composition for the destruction of cancer stem cells carrying the tumor-associated antigen EpCAM and the membrane bound glycoprotein CD 133 in a population of patients suffering from a tumor. | 04-19-2012 |
20130309234 | CORRELATION OF DE NOVO-INDUCED TUMOR-ASSOCIATED HUMORAL IMMUNE RESPONSES WITH IMPROVED CLINICAL OUTCOME - The present invention refers to a method for predicting an improved therapeutic benefit for an individual suffering from a tumor carrying a known tumor-associated cell surface antigen (such as EpCAM). The present invention further refers to a method for the induction of secondary humoral immune responses directed against a second tumor-associated antigen (e.g., another tumor-associated antigen, like HER2/neu) different from the first tumor-associated antigen in an individual suffering from a tumor comprising tumor cells expressing the first tumor-associated antigen, e.g., EpCAM.) | 11-21-2013 |
20140286999 | VACCINE PREPARATION CONTAINING TRIFUNCTIONAL ANTIBODIES WITH ANTIGEN IMMUNOGENICITY ENHANCER PROPERTIES - The present invention refers to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to a specific target antigen(s) for use in a method of immunizing mammals against diseases in which said target antigen(s) is (are) involved, and further to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to (a) specific target antigen (s) which is (are) involved in a disease of a mammal, specifically a human. | 09-25-2014 |
20150037278 | INITIAL RELATIVE LYMPHOCYTE COUNT AS PREDICTIVE BIOMARKER - The invention relates to a method for predicting an improved therapeutic benefit for an individual with a tumor load before initiating an immune therapy which is capable of activating immune cells against said tumor as well as to pharmaceutical compositions for use in this method. | 02-05-2015 |
20150086550 | COMBINATION OF THE APPLICATION OF ANTIBODIES FOR IMMUNOSTIMULATION TOGETHER WITH GLUCOCORTICOIDS - The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid. | 03-26-2015 |